Drug intelligence / Profile preview

CT-45099

Development stage: Discontinued
Lead developer: Sobi
Modality: Small Molecules

Overview

CT-45099 is a small molecule tubulin inhibitor that was originally developed by CTI BioPharma Corp. (formerly Cell Therapeutics, Inc.) for the treatment of various neoplasms. As an anti-cancer agent, it works by binding to tubulin, a structural protein essential for the formation of microtubules during cell division. By inhibiting tubulin polymerization or stability, CT-45099 induces cell cycle arrest and subsequent apoptosis in rapidly dividing cancer cells. Although it was explored as a potential oncology therapeutic, its development has been discontinued globally.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CT-45099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-45099.

Explore the full profile